

Leonardo Giovannoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5773151/publications.pdf>

Version: 2024-02-01

28
papers

2,024
citations

279798

23
h-index

501196

28
g-index

28
all docs

28
docs citations

28
times ranked

1655
citing authors

#	ARTICLE	IF	CITATIONS
1	Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 999-1009.	4.2	138
2	Targeting Interleukin-2 to the Bone Marrow Stroma for Therapy of Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Cancer Immunology Research</i> , 2015, 3, 547-556.	3.4	39
3	The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer. <i>Cell Adhesion and Migration</i> , 2015, 9, 14-21.	2.7	51
4	Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature. <i>Leukemia Research</i> , 2015, 39, 739-748.	0.8	14
5	Armed antibodies for cancer treatment: a promising tool in a changing era. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 113-121.	4.2	28
6	Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19-IL2 Results in Sustained Clinical and Systemic Immunologic Responses. <i>Cancer Immunology Research</i> , 2014, 2, 668-678.	3.4	81
7	Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 867-877.	6.4	40
8	Abundant in vitro expression of the oncofetal ED-B-containing fibronectin translates into selective pharmacodelivery of 131I-L19SIP in a prostate cancer patient. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 35-43.	2.5	24
9	Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma. <i>Journal of Surgical Oncology</i> , 2013, 107, 173-179.	1.7	72
10	Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 447-455.	2.5	92
11	Antibody-Based Delivery of Interleukin-2 to Neovasculature Has Potent Activity Against Acute Myeloid Leukemia. <i>Science Translational Medicine</i> , 2013, 5, 201ra118.	12.4	97
12	Phase 0 Microdosing PET Study Using the Human Mini Antibody F16SIP in Head and Neck Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2013, 54, 397-401.	5.0	47
13	Radretumab Radioimmunotherapy in Patients with Brain Metastasis: A 124I-L19SIP Dosimetric PET Study. <i>Cancer Immunology Research</i> , 2013, 1, 134-143.	3.4	63
14	The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity. <i>British Journal of Cancer</i> , 2013, 109, 1206-1213.	6.4	78
15	Radioimmunotherapy with Radretumab in Patients with Relapsed Hematologic Malignancies. <i>Journal of Nuclear Medicine</i> , 2012, 53, 922-927.	5.0	65
16	A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2011, 17, 7732-7742.	7.0	134
17	Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12. <i>Protein Engineering, Design and Selection</i> , 2010, 23, 653-661.	2.1	33
18	The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , 2010, 46, 2926-2935.	2.8	149

#	ARTICLE	IF	CITATIONS
19	Expression of the oncofetal ED-Bâ€‘containing fibronectin isoform in hematologic tumors enables ED-Bâ€‘targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. <i>Blood</i> , 2009, 113, 2265-2274.	1.4	153
20	A general method for the selection of high-level scFv and IgG antibody expression by stably transfected mammalian cells. <i>Protein Engineering, Design and Selection</i> , 2008, 22, 169-174.	2.1	24
21	Antibody-Mediated Delivery of Interleukin-2 to the Stroma of Breast Cancer Strongly Enhances the Potency of Chemotherapy. <i>Clinical Cancer Research</i> , 2008, 14, 6515-6524.	7.0	102
22	Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. <i>Clinical Cancer Research</i> , 2003, 9, 571-9.	7.0	229
23	HISTIDYL TAGS AND STRUCTURAL STABILIZATION OF LINEAR PEPTIDES. <i>Spectroscopy Letters</i> , 2002, 35, 111-118.	1.0	1
24	Metal ion complexation and folding of linear peptides. <i>Biophysical Chemistry</i> , 2002, 97, 79-86.	2.8	6
25	NMR studies on Ni(II) induced cyclization of a histidine-tagged peptide. <i>Journal of Peptide Science</i> , 2002, 8, 634-641.	1.4	2
26	Recombinant antibodies for the selective targeting of tumor neovasculature. <i>Current Opinion in Drug Discovery & Development</i> , 2002, 5, 204-13.	1.9	1
27	A strategy for the isolation of catalytic activities from repertoires of enzymes displayed on phage 1 Edited by J. Karn. <i>Journal of Molecular Biology</i> , 1999, 286, 617-633.	4.2	107
28	Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. <i>Cancer Research</i> , 1999, 59, 347-52.	0.9	154